DEVELOPMENT OF PATCHES WITH DIFFERENT
FORMUALTION AND DEVELOPMENT OF MUCOADHESIVE SUSTAINED RELEASE BUCCAL TABLETS AND PATCHES OF 5 FLUOROURACIL USING DIFFERENT POLYMERS
... In recent years, delivery of therapeutic agents through mucoadhesive drug delivery system has become highly interesting. Certain drugs have the lack of efficacy due to decreased bioavailability, GI intolerance, ...
12
Formulation and Development of Transdermal Patches of Piroxicam
... Solutions containing polymers in various ratios are used in an organic solvent. Calculated amount of drug is dissolved in half the quantity of same organic solvent. Enhancers in different concentrations are ...
10
DEVELOPMENT AND INVITRO CHARACTERIZATION OF TRANSDERMAL PATCHES OF IMIDAPRIL
... polymeric patches containing dissolved or dispersed drugs that deliver therapeutic agents at a constant rate to the human ...transdermal patches containing imidapril were prepared by solvent casting method ...
13
Formulation Development and Invitro Evaluation of Cimetidine Buccal Patches
... According to these results, it seems apparent that flattened surface cell layers present the main barrier to permeation, while the more isodiametric cell layers are relatively permeable. In both keratinized and ...
109
FORMULATION DEVELOPMENT AND EVALUATION OF CLOPIDOGREL BISULFATE TRANSDERMAL PATCHES
... The influence of varying the combination of polymer concentrations at different ratio was evaluated. The polymers used in this study did not alter physicochemical properties of the drug. All the batches were ...
6
Development and evaluation of matrix type transdermal patches of aspirin
... at different time ...the patches were stuck to an aluminum foil which was previously cut to have a diameter of 2 cm and a slightly larger patch was fixed using an water- impermeable adhesive to ensure that ...
10
Formulation, Development and Characterization of Transdermal Patches of Sitagliptin Phosphate
... The temperature of receptor compartment was maintained at 32±0.5ºC. The samples were withdrawn at different time intervals and analyzed for drug content 250 nm using UV- visible spectrophotometer after suitable ...
6
Development and Evaluation of Transdermal Patches of Quetiapine fumerate for the treatment of psychosis
... PAGE | 472 | contact with the stratum corneum side of the skin; the top side was covered with aluminum foil as a backing membrane. Teflon bead was placed in the receptor compartment filled with 12ml of normal saline. The ...
7
DEVELOPMENT AND EVALUATION OF TRANSDERMAL PATCHES FOR IMPROVED IN-VITRO PERMEATIONOF FESOTERODINE
... Percentage Moisture Uptake: The prepared formulations also demonstrated low moisture absorption, which may protect the formulations from microbial contamination and bulkiness of the patches. The study of the ...
9
DEVELOPMENT AND EVALUATION OF TRANSDERMAL PATCHES WITH CISSUS QUADRANGULARIS PLANT EXTRACT
... transdermal patches of Cissus Quadrangularis ...in different concentrations Di butyl Phthalate and DMSO were used as plasticizers and permeation ...transdermal patches were evaluated for their ...
6
Development and Characterization of Transdermal patches of Propanalol Hydrochloride for the prophylaxis of Migraine
... with different ratio of polymers like Ethylecellulose (EC) , Polyvinyl Pryrrolidone (PVP) and Polyvinyl alcohol (PVA) by the solvent evaporation ...trandermal patches were evaluated with thickness, moisture ...
14
FABRICATION, DEVELOPMENT AND CHARACTERIZATION OF CARVEDILOL TRANSDERMAL PATCHES: AN EMPIRICAL STUDY
... transdermal patches were prepared with combination of different polymers such as EC: PVP K- 30, EC: HPMC K-15M, EC: ...transdermal patches were ...
10
Development and Physicochemical, In Vitro and In Vivo Evaluation of Transdermal Patches of Zaleplon
... The aim of the present work was to develop and evaluate matrix type transdermal therapeutic system of zaleplon (ZLP) with different ratios of hydrophilic and hydrophobic polymeric combinations. Formulations A1, ...
10
DESIGN, DEVELOPMENT AND EVALUATION OF MUCCOADHESIVE PATCHES OF NIFEDIPINE FOR BUCCAL DELIVERY
... Nifedipine patches were prepared using polymers like Chitosan, PVP K 30, PVA, and ...The patches were evaluated for their thickness uniformity, folding endurance, weight uniformity, content uniformity, ...
10
Development And In Vitro Evaluation Of Transdermal Patches Of Lovastatin As A Antilipidemic Drug
... In vitro Drug Release study In vitro drug release studies were performed by using a Franz diffusion cell with a receptor compartment capacity of 22 ml. The cellulose acetate membrane (pore size 0.45µ) was mounted between ...
9
DEVELOPMENT AND IN-VITRO EVALUATION OF MATRIX-TYPE TRANSDERMAL PATCHES OF LOSARTAN POTASSIUM
... The variations in thickness may be due to viscosity of polymer solutions of different formulations. Patch thickness should also be appropriate because increased film thickness will increase compaction and reduce ...
5
Design, Development and Evaluation of Herbal Transdermal Patches for Anti-Inflammatory Activity
... Zero order was found to be dominant mechanism for drug release from the films. Based on in vitro skin permeation studies, CM4 [PEG/EC, 1:5, menthol (36 g): limonene (36l)], was found to be better formulation as it ...
17
DEVELOPMENT EVALUATION AND CHARACTERIZATION OF LOSARTAN POTASSIUM BUCCAL PATCHES USING HYDROPHILIC POLYMERS
... Among different routes of drug delivery buccal route is an attractive alternate for drug administration which provides improved patient compliance and increase bioavailability of drugs undergoing extensive hepatic ...
11
FORMULATION DEVELOPMENT AND IN-VITRO EVALUATION OF MATRIX TYPE TRANSDERMAL PATCHES OF ROSIGLITAZONE MALEATE
... transdermal patches of Rosiglitazone Maleate by using Ethylcellulose and Eudragit as polymers at different combinations to minimize adverse effects associated with oral ...Transdermal patches of ...
9
Development, Characterization and Statistical Optimization of Almotriptan Malate Loaded Transdermal Patches for the Treatment of Migraine
... LITERATURE REVIEW 1. Srilakshmi et al., (2017) developed matrix type transdermal therapeutic system containing Irbesartan, an angiotensin receptor blocker, with different ratios of hydrophilic and hydrophobic ...
109